Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol

ConclusionSerum level of C20:4 is a promising biomarker to predict adverse cardiometabolic responses including glucose and poor antihypertensive response to atenolol.

http://link.springer.com/10.1007/s11306-016-1098-2

Source: Metabolomics - September 14, 2016 Category: Biology Source Type: research